Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMM
Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMM
Julien Grenier, Jean‐Yves Pierga, Philippe Toussaint, F. Viret et al.
Journal
The Breast
Topics
Breast Cancer Treatment Studies
article
Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMM
Julien Grenier, Jean‐Yves Pierga, Philippe Toussaint, F. Viret, David Pérol, Jean‐Philippe Spano, Olivier Trédan, Louis Doublet, Jean‐Sébastien Frenel, Thomas Bachelot, Sylvie Chabaud, Christelle Lévy, Yann Molin, Olfa Derbel, D. Loirat, Anne Patsouris, Pierre-Etienne Heudel, Gwenaële Garin, Christelle Jouannaud, Thierry Petit, Laura Mansi, Jean Marc Ferrero, Aurélien Robert
article en
Abstract
No abstract available for this paper.
Publication Tag
The BreastVol. 85
Institutions
Université Paris Cité (FR), Sorbonne Université (FR), Centre Hospitalier Universitaire de Besançon (FR), Institut de Cancérologie Strasbourg (FR), Centre François Baclesse (LU), Centre Léon Bérard (FR), Institut de Cancérologie de l'Ouest (FR), Pôle Léonard de Vinci (FR), Pitié-Salpêtrière Hospital (FR), Centre François Baclesse (FR), Hôpital Privé Jean Mermo (FR), Centre Hospitalier de Valence (FR), Institut Paoli-Calmettes (FR), Centre Antoine Lacassagne (FR), Hôpital Charles-Foix (FR), Institut Jean Godinot (FR), Institut Sainte Catherine (FR), Institut Curie (FR)